TESA (Tesamorelin) UAE: GHRH Research Guide

TESA (Tesamorelin) is a synthetic GHRH analogue used in published human trials to stimulate pituitary growth hormone release while preserving pulsatile GH dynamics — making it a primary reference compound for UAE researchers studying visceral adiposity, IGF-1 axis signalling, and metabolic endpoints. This guide summarises mechanism, trial evidence, conservative storage (including the 7-day reconstitution window), and documentation checks before sourcing research-grade Tesamorelin in Dubai and the wider UAE.

Below: what TESA is, how it works on the GH–IGF-1 axis, Phase 3 and follow-on trial data with primary citations, comparison to CJC-1295 and Ipamorelin, dosing and storage reference tables, COA verification, and FAQ — all framed for qualified laboratory research contexts only.

02 · TESA

What Is TESA (Tesamorelin)?

Tesamorelin (often abbreviated TESA in peptide research circles) is a synthetic analogue of growth hormone-releasing hormone (GHRH) — the hypothalamic signal that tells the anterior pituitary to secrete growth hormone. The molecule matches native GHRH sequence with an added trans-3-hexenoic acid at the N-terminus, a modification that slows enzymatic degradation and extends circulating half-life relative to native GHRH (PubMed (DOI)).

Because TESA acts upstream at the pituitary, it preserves the normal pulsatile pattern of GH secretion rather than flattening levels the way exogenous GH can. That physiological release profile is why many GH-axis studies prefer GHRH analogues over direct GH for endpoint modelling (PubMed (DOI)).

Among research peptides, Tesamorelin stands out for the depth of published human trial data — particularly visceral adiposity in HIV-associated lipodystrophy, where pooled Phase 3 analyses supported regulatory approval (PubMed (DOI)).

03 · Tesamorelin

How Does Tesamorelin Work on the GH–IGF-1 Axis?

Tesamorelin binds GHRH receptors on somatotroph cells in the anterior pituitary. Receptor activation triggers cAMP-mediated signalling and the pulsatile release of endogenous growth hormone. GH acts on peripheral tissues and stimulates the liver to produce insulin-like growth factor 1 (IGF-1), the primary downstream mediator of GH anabolic and metabolic effects (PubMed (DOI)).

Key mechanisms reported in the literature include:

• Pulsatile GH stimulation — maintains physiologic release dynamics versus continuous GH exposure
• IGF-1 upregulation — measurable within weeks in trial cohorts (PubMed)
• Visceral adipose lipolysis — primary Phase 3 endpoint driver (PubMed (DOI))
• Lean mass preservation — secondary body-composition signals in long trials
• Lipid profile modulation — triglyceride improvements reported alongside VAT loss (PubMed)

04 · Tesamorelin

Tesamorelin Research: Key Studies and Clinical Evidence

Visceral Adiposity and Body Composition

The best-characterised Tesamorelin endpoint is visceral adipose tissue (VAT) reduction. Two Phase 3 randomised trials in HIV-associated lipodystrophy (806 participants pooled) showed significant VAT loss versus placebo — approximately 15–18% — with improved waist circumference and triglycerides (PubMed, PubMed (DOI)). Those data supported FDA approval of Egrifta (tesamorelin) for that specific indication in 2010; research-grade material supplied in the UAE remains for laboratory use outside any approved therapeutic pathway.

Research lane	Primary endpoint	Typical duration	Evidence tier
HIV lipodystrophy VAT	Visceral adipose tissue (MRI/CT)	26 weeks · 2 mg/d	Phase 3 RCT · regulatory path
IGF-1 axis	Serum IGF-1 pharmacodynamics	2–26 weeks	Multiple published cohorts
NAFLD	Liver fat fraction (MRI-PDFF)	26 weeks	Placebo-controlled RCT
Cognitive (MCI)	Neuropsych battery subsets	20+ months	Exploratory RCT
Body composition (general)	Lean mass + VAT composite	Varies by model	Preclinical + secondary human data

IGF-1 and GH Axis Restoration

Trials consistently report IGF-1 elevation within the first weeks of daily Tesamorelin, with values returning toward baseline after discontinuation — consistent with a secretagogue mechanism rather than exogenous GH replacement (PubMed). Researchers modelling age-related GH-axis decline often track IGF-1 as a pharmacodynamic biomarker alongside body-composition imaging.

Cognitive Function Research

A randomised trial in older adults with mild cognitive impairment reported exploratory cognitive improvements after extended Tesamorelin exposure, with authors discussing IGF-1-mediated neurotrophic signalling (PubMed (DOI)). This line of research remains active; it does not establish any approved cognitive indication and should be read as hypothesis-generating trial data only.

Non-Alcoholic Fatty Liver Disease (NAFLD)

A placebo-controlled trial in The Lancet Diabetes & Endocrinology reported significant liver-fat reduction with Tesamorelin in NAFLD cohorts (PubMed (DOI)). Hepatic endpoints overlap with the VAT literature (PubMed) and remain a focus for metabolic research models — again, not therapeutic claims for UAE buyers.

05 · TESA

TESA vs CJC-1295, Ipamorelin and Other GH Secretagogues

UAE labs often stack or compare GHRH-pathway and ghrelin-pathway secretagogues. Use published mechanism differences — not marketing labels — when designing a study matrix:

For a dedicated comparison write-up, see our CJC-1295 + Ipamorelin UAE guide. Many GH-axis protocols in the literature combine a GHRH analogue with a ghrelin mimetic to target complementary receptor populations — always anchor combinations to primary sources.

06 · Tesamorelin

Tesamorelin Dosing Protocol (Research Reference)

The following summarises published trial administration schedules for research literacy only. It is not instructions for human use.

Phase 3 programmes administered 2 mg subcutaneous daily, commonly in the evening to align with nocturnal GH pulses (PubMed). Lower doses (1 mg) appear in some exploratory cohorts; always cite the primary paper when reproducing a model.

Emirates Peptides supplies lyophilised Tesamorelin for laboratory research. Use the peptide reconstitution calculator with bacteriostatic water to model concentrations before any in-vitro or animal work.

Study context	Dose	Route	Duration	Notes
Phase 3 HIV lipodystrophy	2 mg	SC daily	26 weeks	Primary VAT endpoint trials
Exploratory GH-axis models	1–2 mg	SC daily	12–52 weeks	Cite primary paper per model
Reconstitution reference	—	BAC water	Use ≤ 7 days	2–8 °C after mixing
Timing convention	Evening dose	SC	—	Aligns with nocturnal GH pulse literature

Storage Guidelines (UAE Climate Note)

For general peptide cold-chain handling in Gulf conditions, cross-read our peptide storage and handling guide.

07 · Glossary

Glossary: TESA and GH-Axis Terms

• TESA: Research shorthand for Tesamorelin — not a separate compound.
• GHRH: Growth hormone-releasing hormone; hypothalamic peptide that signals pituitary GH secretion.
• GH: Growth hormone (somatotropin) released from anterior pituitary somatotrophs.
• IGF-1: Insulin-like growth factor 1; primary hepatic downstream marker of GH action.
• VAT: Visceral adipose tissue — central fat depot targeted in Phase 3 Tesamorelin trials.
• Secretagogue: Agent that stimulates endogenous release (here, GH) rather than replacing the hormone.
• Lyophilised: Freeze-dried powder form — standard for research peptide distribution.
• COA: Certificate of Analysis — batch-specific purity document; required for institutional receiving.

08 · Research

UAE Research Compliance Notes

Institutional buyers in the UAE should treat Tesamorelin like any imported research reagent: verify end-user research credentials, maintain temperature logs on receipt, and store COA PDFs with batch IDs. Emirates Peptides materials are labelled for laboratory research only and must not be repackaged or represented for clinical, cosmetic, or athletic use. If your protocol requires ethics approval, obtain it before ordering — supplier documentation supports traceability, not protocol sign-off.

09 · TESA

Why TESA Is a Priority Research Compound in the UAE

Regional research interest clusters around metabolic health, body composition, and longevity science — all areas where the GH–IGF-1 axis is actively modelled:

10 · Tesamorelin

Tesamorelin Quality, COA and Purity Standards

A 44-amino acid chain demands rigorous analytical release testing. Before any TESA batch enters your workflow, verify:

11 · Research-Grade

Where to Buy Research-Grade Tesamorelin in the UAE

Emirates Peptides supplies COA-accompanied Tesamorelin for qualified laboratory researchers across the UAE and GCC. Each batch is independently HPLC-verified, lyophilised under controlled conditions, and shipped with documentation suitable for institutional receiving checks.

• COA-verified, ≥99% purity on release
• Same-day dispatch for Dubai orders before 2 pm UAE time
• GCC shipping (Saudi Arabia, Oman, Qatar, Kuwait, Bahrain)
• Documentation-first packaging for research institutions

View Tesamorelin product page (research supply) →

12 · Questions

Frequently Asked Questions

Disclaimer: For laboratory research and educational context only. Not for human consumption and not medical advice. Researchers are responsible for institutional approvals and local regulations.